A pre-IND meeting is valuable when it resolves the questions that would otherwise put your IND, timeline or development plan at risk. Too many sponsors use it to present their program rather than to settle uncertainty. The agency responds to the questions you ask, so the real work is in choosing and framing them.
What is a pre-IND meeting for?
FDA offers pre-IND meetings, a Type B meeting category, so sponsors can discuss their development plans before submitting an IND. Typical topics include whether the nonclinical package supports the proposed first-in-human dose and duration, the CMC information appropriate for the phase, the design of the initial clinical study and any special considerations for the program. Depending on the request, the agency may respond in writing rather than meet.
How do you choose the right questions?
Ask about decisions you are about to make that are expensive to reverse. "Does the agency agree that the proposed nonclinical program supports a starting dose of X, based on Y?" is a strong question. "Does FDA have comments on our program?" invites broad, unpredictable feedback.
Make each question specific, with your proposal and the rationale behind it.
Prioritize. Fewer, sharper questions get clearer answers.
Include questions that unlock operational decisions, such as the proposed safety monitoring, sentinel dosing or escalation scheme.
Avoid asking what existing guidance already answers.
What goes into a strong briefing package?
Concise background, a product description, a summary of nonclinical findings, a CMC overview and the proposed clinical plan. For each question, state the sponsor's position and the data supporting it. A reviewer should understand exactly what you are asking without hunting through appendices.
Why should clinical operations be involved?
Agency feedback can reshape the study: additional safety monitoring, a different starting dose, longer follow-up. Every one of those has operational consequences for site capability, budget and timeline. When clinical operations helps shape the questions, the team can anticipate likely responses and prepare scenarios. After the meeting, the same people translate the feedback into protocol and vendor decisions.
What should happen after the meeting?
FDA issues official minutes after a formal meeting. Take your own detailed notes and compare them carefully when the minutes arrive. Then circulate a short decision log: what we heard, what we are changing and who owns each change. Update the timeline and risk register accordingly.
What are the most common pitfalls?
Requesting the meeting too late to act on the feedback. Asking questions that are too broad. Overloading the package. Not rehearsing the discussion. And treating feedback as optional, or assuming advice is a guarantee. Advice reflects the information presented at the time, so a sponsor that changes course afterward should think carefully about whether to return to the agency.
Planning the path to your first IND? Explore ABRA's services for emerging sponsors.
